Jun Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Ji has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Boyu Liu
Department of Anesthesiology, Air Force Medical Center, Beijing, China
1 shared publicationChaoping Guo
Department of Anesthesiology, Air Force Medical Center, Beijing, China
1 shared publicationHang Yang
Department of Anesthesiology Air force medical center Beijing China
1 shared publication- Lu Gao
Department of Physiology, Naval Medical University, Shanghai, China
1 shared publication - Rongrong Li
Department of Anesthesiology, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China
1 shared publication Shengxiang Wang
Department of Anesthesiology, Air Force Medical Center, Beijing, China
1 shared publication
Latest Publications
- Open Access
Chronic Alcoholism and Propofol Demand: The Impact of Alcohol Tolerance in Painless Gastrointestinal Endoscopy
Background and Aim: Existing research suggests that chronic alcohol consumption may increase propofol requirements during anesthesia, though findings remain inconsistent. This study investigated the influence of chronic ethanol intake and alcoholic tolerance on propofol dosage in patients undergoing painless gastrointestinal endoscopy. Methods: One hundred male patients with habitual alcohol consumption were enrolled. Drinking behavior was assessed using the Alcohol Use Disorders Identification Test (AUDIT), and alcohol tolerance was also assessed by self‐reporting. Propofol was infused using a bispectral index (BIS)‐guided closed‐loop target‐controlled infusion system during induction and maintenance of anesthesia. The depth of anesthesia was controlled to maintain a BIS value of 60 ± 5, and the target plasma and effect‐site concentrations were recorded throughout the procedure. Results: Patients with high alcohol tolerance, but not hazardous drinking behavior, consumed higher propofol doses and exhibited higher effect‐site concentrations during anesthesia induction (BIS reach 60), maintenance (10 min post induction), and recovery (eye‐opening under stimuli). Both higher alcohol tolerance and hazardous drinking behavior were associated with shorter recovery times. Conclusions: Propofol requirements are increased in patients with high alcohol tolerance during painless gastrointestinal endoscopy. The mechanisms underlying this association, including potential pharmacodynamic adaptations, warrant further investigation.
Open AccessChronic Alcoholism and Propofol Demand: The Impact of Alcohol Tolerance in Painless Gastrointestinal Endoscopy
Background and Aim: Existing research suggests that chronic alcohol consumption may increase propofol requirements during anesthesia, though findings remain inconsistent. This study investigated the influence of chronic ethanol intake and alcoholic tolerance on propofol dosage in patients undergoing painless gastrointestinal endoscopy. Methods: One hundred male patients with habitual alcohol consumption were enrolled. Drinking behavior was assessed using the Alcohol Use Disorders Identification Test (AUDIT), and alcohol tolerance was also assessed by self‐reporting. Propofol was infused using a bispectral index (BIS)‐guided closed‐loop target‐controlled infusion system during induction and maintenance of anesthesia. The depth of anesthesia was controlled to maintain a BIS value of 60 ± 5, and the target plasma and effect‐site concentrations were recorded throughout the procedure. Results: Patients with high alcohol tolerance, but not hazardous drinking behavior, consumed higher propofol doses and exhibited higher effect‐site concentrations during anesthesia induction (BIS reach 60), maintenance (10 min post induction), and recovery (eye‐opening under stimuli). Both higher alcohol tolerance and hazardous drinking behavior were associated with shorter recovery times. Conclusions: Propofol requirements are increased in patients with high alcohol tolerance during painless gastrointestinal endoscopy. The mechanisms underlying this association, including potential pharmacodynamic adaptations, warrant further investigation.
- Open Access
- 8 January 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 1-8
Prevention of sufentanil-induced cough during induction of general anesthesia by low-dose esketamine
Sufentanil is commonly used to induce general anaesthesia due to its rapid onset of action, strong analgesic effect, long-lasting effect, and stable haemodynamics; however, it often induces cough, increasing the risk of anaesthesia. This study aimed to investigate the preventive effect of low-dose esketamine on sufentanil-induced cough. This randomised, double-blind, placebo-controlled clinical study was conducted at the Air Force Medical Center between September 2023 and May 2024. A total of 100 adult patients (ASA of Anaesthesiologists class I–II) required general anaesthesia for elective surgery. The patients were randomly assigned to two groups: the esketamine group (Group E, n = 50), receiving 0.2 mg/kg esketamine intravenously, and the control group (Group C, n = 50), receiving an equal volume of normal saline. The incidence and severity of sufentanil-induced cough were assessed 1 min after administering of 0.5 μg/kg sufentanil intravenously. Heart rate (HR), mean arterial pressure (MAP), and adverse reactions were recorded at four time points: before esketamine administration (T0), 3 min after esketamine administration (T1), 1 min after endotracheal intubation (T2), and 3 min after endotracheal intubation (T3). The results were analyzed using appropriate statistical methods. A total of 100 eligible patients were screened, of which 99 participated in this study (1 patient refused to participate), 50 in Group E, and 49 in Group C. The incidence of cough in Group E (6.0%) was significantly lower than that in Group C (34.7%) (P < 0.001), and the severity of cough was also significantly milder than that in Group C (P = 0.038). The differences in the HR and MAP levels at T0, T1, T2, and T3 between the two groups were not statistically significant (P > 0.05). Two patients in Group C experienced chest wall stiffness, while no adverse reactions were observed in Group E. The difference in the incidence of adverse reactions between the two groups was not statistically significant (P > 0.05). Low-dose esketamine (0.2 mg/kg) can significantly reduce the incidence of sufentanil-induced cough during the induction of general anaesthesia in patients, with a small impact on haemodynamics, no adverse reactions, and good safety.
- 8 January 2025
- Published by Springer Nature in BMC Anesthesiology
- Vol. 25 (1) , 1-8
Open AccessPrevention of sufentanil-induced cough during induction of general anesthesia by low-dose esketamine
Sufentanil is commonly used to induce general anaesthesia due to its rapid onset of action, strong analgesic effect, long-lasting effect, and stable haemodynamics; however, it often induces cough, increasing the risk of anaesthesia. This study aimed to investigate the preventive effect of low-dose esketamine on sufentanil-induced cough. This randomised, double-blind, placebo-controlled clinical study was conducted at the Air Force Medical Center between September 2023 and May 2024. A total of 100 adult patients (ASA of Anaesthesiologists class I–II) required general anaesthesia for elective surgery. The patients were randomly assigned to two groups: the esketamine group (Group E, n = 50), receiving 0.2 mg/kg esketamine intravenously, and the control group (Group C, n = 50), receiving an equal volume of normal saline. The incidence and severity of sufentanil-induced cough were assessed 1 min after administering of 0.5 μg/kg sufentanil intravenously. Heart rate (HR), mean arterial pressure (MAP), and adverse reactions were recorded at four time points: before esketamine administration (T0), 3 min after esketamine administration (T1), 1 min after endotracheal intubation (T2), and 3 min after endotracheal intubation (T3). The results were analyzed using appropriate statistical methods. A total of 100 eligible patients were screened, of which 99 participated in this study (1 patient refused to participate), 50 in Group E, and 49 in Group C. The incidence of cough in Group E (6.0%) was significantly lower than that in Group C (34.7%) (P < 0.001), and the severity of cough was also significantly milder than that in Group C (P = 0.038). The differences in the HR and MAP levels at T0, T1, T2, and T3 between the two groups were not statistically significant (P > 0.05). Two patients in Group C experienced chest wall stiffness, while no adverse reactions were observed in Group E. The difference in the incidence of adverse reactions between the two groups was not statistically significant (P > 0.05). Low-dose esketamine (0.2 mg/kg) can significantly reduce the incidence of sufentanil-induced cough during the induction of general anaesthesia in patients, with a small impact on haemodynamics, no adverse reactions, and good safety.
- Open Access
- 22 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (6) , 1148
Stellate Ganglion Block Attenuates LPS-Induced Acute Lung Injury by Activating Sirt3 Regulation of Oxidative Stress and Inflammation
Stellate ganglion blocks (SGBs) has been applied in clinics to alleviate pain-related syndromes for almost a century. In recent years, it has been reported that SGB can attenuate acute lung injury (ALI) in animals. However, the details of these molecular mechanisms remain complex and unclear. In this study, rats were randomly divided into four groups: group C (receiving no treatment), group NS (receiving the intratracheal instillation of normal saline), group L (receiving the intratracheal instillation of LPS) and group LS (receiving SGB after the intratracheal instillation of LPS). The pathological damage of lung tissue, arterial blood gases, the differentiation of alveolar macrophages (AMs) and inflammatory cytokines (IL-1β, IL-6, IL-10) were detected. Furthermore, the oxidative stress indexes (ROS, CYP-D, T-SOD, Mn-SOD and CAT) in serum and the levels of Sirt3 signaling-associated proteins (JAK2/STAT3, NF-κb p65, CIRP and NLRP3) in the lungs were measured. The results revealed that SGB could attenuate lung tissue damage, improve pulmonary oxygenation, promote the differentiation of AMs to the M2 phenotype, decrease the secretion of IL-1β and IL-6, and increase the secretion of IL-10. Meanwhile, SGB was found to inhibit the production of ROS and CYP-D, and enhance the activities of T-SOD, Mn-SOD and CAT. Furthermore, SGB upregulated Sirt3 and downregulated JAK2/STAT3 and NF-κb p65 phosphorylation, CIRP and NLRP3. Our work revealed that SGB could attenuate LPS-induced ALI by activating the Sirt3-mediated regulation of oxidative stress and pulmonary inflammation; this may shed new light upon the protection of SGB and provide a novel prophylactic strategy for LPS-induced ALI.
- 22 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (6) , 1148
Open AccessStellate Ganglion Block Attenuates LPS-Induced Acute Lung Injury by Activating Sirt3 Regulation of Oxidative Stress and Inflammation
Stellate ganglion blocks (SGBs) has been applied in clinics to alleviate pain-related syndromes for almost a century. In recent years, it has been reported that SGB can attenuate acute lung injury (ALI) in animals. However, the details of these molecular mechanisms remain complex and unclear. In this study, rats were randomly divided into four groups: group C (receiving no treatment), group NS (receiving the intratracheal instillation of normal saline), group L (receiving the intratracheal instillation of LPS) and group LS (receiving SGB after the intratracheal instillation of LPS). The pathological damage of lung tissue, arterial blood gases, the differentiation of alveolar macrophages (AMs) and inflammatory cytokines (IL-1β, IL-6, IL-10) were detected. Furthermore, the oxidative stress indexes (ROS, CYP-D, T-SOD, Mn-SOD and CAT) in serum and the levels of Sirt3 signaling-associated proteins (JAK2/STAT3, NF-κb p65, CIRP and NLRP3) in the lungs were measured. The results revealed that SGB could attenuate lung tissue damage, improve pulmonary oxygenation, promote the differentiation of AMs to the M2 phenotype, decrease the secretion of IL-1β and IL-6, and increase the secretion of IL-10. Meanwhile, SGB was found to inhibit the production of ROS and CYP-D, and enhance the activities of T-SOD, Mn-SOD and CAT. Furthermore, SGB upregulated Sirt3 and downregulated JAK2/STAT3 and NF-κb p65 phosphorylation, CIRP and NLRP3. Our work revealed that SGB could attenuate LPS-induced ALI by activating the Sirt3-mediated regulation of oxidative stress and pulmonary inflammation; this may shed new light upon the protection of SGB and provide a novel prophylactic strategy for LPS-induced ALI.